conivaptan
Enable an agent to recognise conivaptan, assess the identity and fitness of a material containing it, and identify evidence and restrictions relevant to its intended use.
Bundle → Layer → Finding → Questions Filled
5 bundles · 9 layers · 15 findings · 29 questions
Conivaptan identity Establish what the registered name denotes and how physical material relates to that identity.
Molecular recognition
Reconcile names and identifiers against molecular structure.
Identity anchor
Use a structure-backed identity record to resolve conivaptan and development-code aliases.
- Which verified structure and identifier records anchor vr.tr.conivaptan? definition
- What source establishes that an alias such as YM-087 denotes the same chemical entity? provenance
Salt and product boundaries
Distinguish active moiety, material form and finished medicine.
Composition basis
Represent hydrochloride as a specified relationship or material form and preserve the basis of every reported amount.
- Does this record describe neutral conivaptan, a characterised salt or a mixture containing it? boundary
- Are reported masses expressed as conivaptan equivalents or as the complete salt, including any water or solvent? measurement
Conivaptan material fitness Assess the composition and condition of a specific conivaptan sample.
Assay and impurities
Establish lot-level identity, content and contaminants.
Analytical release evidence
Require methods and acceptance criteria appropriate to the declared conivaptan material and intended use.
- Which identity tests and reference standard support this lot's conivaptan assignment? provenance
- What are the measured conivaptan content, related substances, residual solvents and water content? measurement
- Which documented acceptance criteria determine whether this lot is suitable for its intended use? action
Phase, solubility and stability
Attach physical properties to the exact form and conditions tested.
Condition-dependent properties
Treat dissolution, precipitation and degradation as evidence-dependent behaviours of the specified conivaptan material.
- What phase, solid form and thermal behaviour were measured, and under what conditions? measurement
- What solubility and stability data apply to this form at the proposed solvent, pH, concentration and temperature? measurement
- What evidence supports continued storage, retesting or rejection after a recorded excursion? action
Conivaptan biological action Capture target activity and interaction evidence with its experimental limits.
Vasopressin antagonism
Separate receptor binding, functional antagonism and downstream responses.
Dual-target evidence
Record V1a and V2 results separately, including assay conditions and uncertainty.
- Which assays establish conivaptan binding and functional antagonism at V1a and V2? provenance
- What potency values apply to each receptor, species and assay endpoint? measurement
- Which measured responses support aquaretic activity, and which remain inferred from receptor results? boundary
Exposure and interactions
Link substance-level disposition evidence to product-specific restrictions.
CYP3A interaction context
The 2017 product label contraindicates potent CYP3A inhibitors and generally advises avoiding CYP3A substrates; retain the product and version context. [Vaprisol prescribing information](https://www.vaprisol.com/pdf/vaprisol-pi-sept2017.pdf)
- Which studies establish conivaptan's roles as a metabolic substrate and enzyme inhibitor? provenance
- What exposure changes were measured for each interaction, formulation and population? measurement
- Which interaction conclusions require review through the applicable medicinal-product model before use? action
Conivaptan use constraints Connect material hazards and documented medicinal use to bounded agent decisions.
Handling and regulatory identity
Resolve hazard evidence and regulatory records for the actual material form.
Form-specific hazard evidence
Record applicable safety documentation without inferring occupational limits or GHS categories from therapeutic activity.
- Which current safety data sheet covers this conivaptan form, concentration and supplier material? provenance
- Which EC, regulatory substance and hazard-classification records apply in the intended jurisdiction? definition
- What handling, containment and disposal measures are supported, and is an exposure limit actually established? action
Medicinal use interface
Link the substance to authorised products and their clinical evidence.
Product evidence boundary
The 2017 Vaprisol label addresses hospital treatment of euvolemic or hypervolemic hyponatremia and warns about overly rapid sodium correction; these are product-context claims. [Vaprisol prescribing information](https://www.vaprisol.com/pdf/vaprisol-pi-sept2017.pdf)
- Which authorised product, jurisdiction and label revision support the proposed medicinal-use relationship? provenance
- Which claims concern conivaptan itself, and which depend on formulation, route or patient population? boundary
- What product and clinical-care records must be consulted before any administration decision? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of conivaptan this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of conivaptan this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of conivaptan this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of conivaptan this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of conivaptan this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of conivaptan this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of conivaptan this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Conivaptan is a synthetic, nonpeptide antagonist of vasopressin V1A and V2 receptors, administered intravenously as its hydrochloride salt to promote electrolyte-free water excretion in the treatment of euvolemic and hypervolemic hyponatremia.
In scope
- Conivaptan molecular identity and identifier reconciliation
- Free-base identity and relationships to salts, including hydrochloride
- Sample composition, purity, grade and analytical evidence
- Physical state, solubility and stability under recorded conditions
- Vasopressin receptor activity and substance-level interaction evidence
- Form-specific handling hazards and jurisdiction-specific regulatory identifiers
Out of scope
- Vaprisol formulation, packaging and finished-product release
- Patient diagnosis, treatment selection, dosing and monitoring plans
- Manufacturing process design and production equipment
- Independent models of vasopressin receptors and hyponatremia
- Supplier organisations and commercial transactions
Why it exists Filled
Enable an agent to recognise conivaptan, assess the identity and fitness of a material containing it, and identify evidence and restrictions relevant to its intended use.
Distinguishing features Filled
- Match molecular structure to conivaptan, PubChem CID 151171 and CAS 210101-16-9; the name or suffix alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Conivaptan)
- The neutral molecule has formula C32H26N4O2 and molecular weight approximately 498.6 g/mol; hydrochloride material requires an explicitly different composition basis. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Conivaptan)
- Require evidence of the characteristic dual V1a/V2 vasopressin antagonist profile when distinguishing pharmacological function; activity alone does not establish chemical identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Conivaptan)
- Distinguish conivaptan material from a finished intravenous product containing conivaptan hydrochloride and excipients. [Vaprisol prescribing information, revised September 2017](https://www.vaprisol.com/pdf/vaprisol-pi-sept2017.pdf)
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust an infusion without a clinician's decision.
- Ignore a rapid rise in blood sodium during treatment.
- Overlook interactions with drugs metabolised by the same liver enzymes.
Only with a human decision
- Starting, stopping or changing an infusion.
May
- Describe conivaptan's mechanism and its hospital use for low blood sodium.
- Support clinical teams with sodium monitoring records they have authorised.
Moral aspects Filled
- Correcting sodium too fast can cause permanent brain injury, so patient safety depends on close monitoring.
Who is affected
- Hospital patients
- Families
- Clinical staff
Owners Filled
Steward
The marketing authorisation holder where it is licensed; the treating clinician answers for each use.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.conivaptan
- Wikidata: Q5161126 (https://www.wikidata.org/wiki/Q5161126)
Direct properties required Filled
- Chemical identity: Structure identifier with reconciled CAS, PubChem and regulatory records
- Material form: Free base, specified salt, hydrate, solvate or unresolved form
- Conivaptan content: % w/w or mg/mL; specify free-base or salt basis and analytical method
- Impurity profile: Individual and total impurities in % w/w or ppm, with detection limits
- Physical and solid-state condition: Observed phase and characterised solid form at stated temperature and humidity
- Solubility: mg/mL or mol/L with solvent, pH, temperature, form and equilibration method
- Stability: Assay and degradant changes over time under specified storage conditions
- Vasopressin receptor activity: V1a and V2 Ki, IC50 or functional potency in nM, with assay context
- Use eligibility: Supported, restricted, unsupported or unresolved for a specified use
Recognition required Filled
- A solution for intravenous infusion; identity is confirmed by label and pharmacy records.
Capabilities and actions required Filled
- Reconcile a labelled sample with conivaptan identity records and analytical results.
- Normalise a reported quantity to conivaptan equivalents when salt stoichiometry, purity and water content are known.
- Assess whether a lot satisfies documented requirements for an intended research or manufacturing use.
- Compare solubility and stability evidence under matching material and environmental conditions.
- Flag pharmacological interactions and route clinical decisions to the linked product and care models.
- Identify missing evidence that requires testing, retesting or withholding a suitability conclusion.
Hazards and failure modes required Filled
- Overly rapid sodium correction can cause osmotic demyelination.
- Infusion site reactions.
- Drug interactions through liver enzyme inhibition.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology assigns conivaptan the code C03XA02 within vasopressin antagonists.
Context of use required Filled
- Conivaptan is encountered in pharmaceutical research, analytical testing and medicinal products as a vasopressin receptor antagonist.
- Its hydrochloride salt is used intravenously in monitored clinical care for specified forms of hyponatremia, subject to the applicable product authorisation.
Sources Filled
- Wikidata item Q5161126: conivaptan - identity and sense of the item
- Wikipedia: Conivaptan - general description of the item
Open questions
- Does an existing Vercy world model already cover conivaptan, and how should the registry link to it without duplicating ownership?
- Which verified salt, hydrate, solvate or polymorph forms need representation, and what experimental solubility and thermal data apply to each?
- Which authoritative analytical specifications define acceptable impurities, degradation limits and grades for conivaptan materials?
- Which current jurisdiction-specific substance identifiers, GHS classifications and occupational exposure limits are established rather than supplier assumptions?
- What current product authorisations and primary pharmacology studies supersede or supplement the identity records and September 2017 label consulted for this draft?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q5161126/spec.json